The CBC is pleased to announce that George Church, PhD, Professor of Genetics at Harvard Medical School and Director of PersonalGenomes.org, which provides the world's only open-access information on human Genomic, Environmental & Trait data (GET), will be the Distinguished Speaker at our BioCapital Summit on November 7th! Church's groundbreaking work in genomics and synthetic biology has laid the foundation for numerous drug discovery efforts. His 1984 Harvard PhD included the first methods for direct genome sequencing, molecular multiplexing & barcoding. These led to the first genome sequence (pathogen, Helicobacter pylori) in 1994. His innovations have contributed to nearly all "next-generation" DNA sequencing methods, the founding of biotech companies (CGI-BGI, Life Technologies, Illumina, Oxford Nanopore Technologies), and his research has advanced our understanding of genetic diseases, enabling the development of targeted therapies. Church's contributions are significant not only to drug discovery and commercialization, but also in his active role in founding and advising biotech companies. His work exemplifies how research can be translated into potential therapeutic applications, which is the core mission of the CBC! Learn more about our exclusive BioCapital Summit at https://lnkd.in/gY5X_Rfj #CBCSummit24
Chicago Biomedical Consortium
Biotechnology Research
Evanston, IL 3,232 followers
Stimulating scientific collaboration to accelerate biomedical discovery in the Chicago ecosystem.
About us
The mission of the Chicago Biomedical Consortium is to stimulate collaboration among scientists at Northwestern University, the University of Chicago, and the University of Illinois Chicago that will transform research at the frontiers of biomedicine. The CBC will: >> Stimulate research and education that bridge institutional boundaries. >> Enable collaborative and interdisciplinary research that is beyond the range of a single institution. >> Recruit and retain a strong cadre of biomedical leaders and researchers in Chicago. >> Promote the development of the biomedical industry in Chicago. >> Execute a plan capable of improving the health of citizens of Chicago and beyond. The CBC gratefully acknowledges support from the Searle Funds at The Chicago Community Trust.
- Website
-
https://chicagobiomedicalconsortium.org/
External link for Chicago Biomedical Consortium
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Evanston, IL
- Type
- Nonprofit
- Founded
- 2001
Locations
-
Primary
2205 Tech Dr., Cook 3133
Evanston, IL 60208, US
Employees at Chicago Biomedical Consortium
-
Chris Leo
Life Sciences Strategy Consultant & Leader of Firm Operations
-
Scott Galasinski
Science and business leader with a passion to create meaningful treatments for unmet medical need
-
James Kasuboski
Venture Capitalist & Bioentrepreneur
-
Luisa Ann "Lu" DiPietro
Professor at University of Illinois Chicago
Updates
-
Calling all startups, #founders, & would-be startup founders—hot off the REACH (Research Evaluation and Commercialization Hub) wires - the Biotech Blueprint Webinar Series hosted by the National Heart, Lung, and Blood Institute has a range of topics for scientists interested in moving their research into the startup scene. Register: https://bit.ly/4gcFLKQ As a REAChub ourselves, CBC-HITES is committed to helping #ChicagoBiotech scientist entrepreneurs move their research from the lab bench to the clinic. Contact us to find out more! #SBIR #STTR #translationalScience #Medtech
-
🚀 Attention Faculty at Loyola University Chicago, Illinois Institute of Technology, Northern Illinois University, Rosalind Franklin University of Medicine and Science, Rush University, and Discovery Partners Institute!* The Windy City Innovation Award offers a unique opportunity to secure up to $75,000 in funding for your innovative research in therapeutics, diagnostics, medical devices, health IT, or research tools. This isn’t just another grant—it’s a full support system designed to help you overcome commercialization challenges and help move your innovations to market. Don’t miss the October 1, 2024 deadline—apply today and take your research to the next level! https://lnkd.in/gB3sE38X
-
The Fireside chats at the Chicago BioCapital Summit are going to be 🔥! Erandi De Silva, PhD, Co-Founder of Forge Biologics and Partner at Drive Capital, will chat with Shobha Parthasarathi, Founder of Intovis, Advisor to Novo Nordisk’s Bio Innovation Hub, and Venture Partner at the Harrington Discovery Institute at University Hospitals . Having helped scale Forge Therapeutics, a high-tech gene therapy manufacturer and clinical stage company, from 3 to 300+ people leading to a $620M exit in less than four years, Erandi will discuss how she did it in the Midwest. Shobha, former Vice President, Strategic Alliances and Business Development at Harrington Discovery Institute (academia), Vice President, External Innovation and New Ventures, Xontogeny (VC), on the advisory board of Novo Nordisk’s BioInnovation hub (industry), and Senior Director at the North Carolina Biotechnology Center (NCBiotech) Center will explore with Erandi how the Midwest can gain traction and establish its position in the larger #biotech/ #biopharma ecosystem. Learn more about our exclusive BioCapital Summit here: https://lnkd.in/gXziGSA4 #CBCSummit24
-
Level up your #scienceCareer at STEMPeers ®'s 1-day career fair for #PhD life scientists. There's an amazing lineup of speakers discussing a diverse array of topics in #science #careers. Our very own Dr Eleonora Gatta, Ph.D is speaking at the roundtable! https://lnkd.in/dUNbVcn3
-
BioCentury Inc. Grand Round Day 2! We're starting out strong with the morning workshop on "Getting Corporate Formation Right." The discussion is focused on what scientific founders need to understand prior to forming a life science company. At the CBC, we provide industry-level expertise, analysis, and guidance to researchers to help them make the right choices and take the right steps to ensure what they build will be attractive to future partners and investors. Great insights from jory bell from Playground Global, Chris Garabedian from Xontogeny, Guru Laxmikanthan at Nutter, Art Pappas from Pappas Capital and Jim Ray from the MD Anderson Cancer Center. Shout out to Eric Pierce from BioCentury for leading a great discussion!
-
👥 Collaboration is at the heart of the CBC mission, and there’s no better place to foster it than at BioCentury Inc.'s Grand Rounds event that starts today! We asked our Senior Director of Translation, Eric Schiffhauer, PhD what he was most excited for while attending Grand Rounds: "As an organization poised at the intersection of academia, industry, and investment in Illinois, the Chicago Biomedical Consortium is excited to share and learn from like minded decision makers in the BioPharma space at BioCentury GrandRounds in Nashville." "I'm looking forward to exploring how to choose the right targets and approaches, accelerate translational timelines, convert academic innovation into drug discovery assets and companies, and train the next generation of BioEntrepreneurs." Send Eric a message on LinkedIn if you will be in Nashville and would like to meet up. #BioCenturyGrandRounds
-
CBC Newsletter is out! Lots of events and lots of #translationalScience funding opportunities. Check it out here: chicago-biomedical-consortium-newsletter-august-26-11184032 Subscribe to stay in the loop! https://bit.ly/4b2pvIX #LifeSciences #Biotech #ChicagoBiotech
-
We're thrilled that Dr. Ted W. Love, MD, Chair of Biotechnology Innovation Organization’s Board of Directors and former President and CEO of Global Blood Therapeutics (GBT), will deliver a keynote address at the Chicago Biomedical Consortium's BioCapital Summit. During his tenure at GBT, Dr. Love played a pivotal role in developing and approval of Oxbryta®, a groundbreaking therapy for sickle cell disease that has significantly impacted patients' lives. With an illustrious career spanning leadership roles at Genentech, Onyx Pharmaceuticals, Inc., an Amgen subsidiary and Gilead Sciences, Dr. Love brings a wealth of expertise in biopharmaceutical development and innovation. Learn more about our exclusive BioCapital Summit by visiting https://lnkd.in/gXziGSA4 #CBCSummit24
-
We’re excited to attend BioCentury Inc’s Grand Rounds conference next week in Nashville! The latest episode of BioCentury This Week gave us a sneak peek into the powerhouse lineup and key trends that will be highlighted. https://lnkd.in/gMpBFciP Hosting this conference in Nashville is significant to us at the CBC, as it underscores the high-impact scientific research happening in the Midwest and our commitment to accelerating the translation of these projects. We're particularly excited by McKinsey & Company’s report preview by Guang Yang, which tackles crucial questions like: "How can we overcome bottlenecks in the translation process?", "Is funding reaching the most translatable experiments?", and "How can we shorten timelines to bring innovations to market?" These are core challenges that the CBC is actively addressing through our model and processes. We are proud to have BioCentury as a supporting organization for our upcoming BioCapital Summit in November, and we’re eager to continue the critical discussions and build on the momentum from Grand Rounds. Learn more about our exclusive BioCapital Summit here: https://lnkd.in/gXziGSA4
Ep. 248 - Grand Rounds Preview: Eyes on the Target
https://spotify.com